Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

News Conference News AHA 2021

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

Yael L. Maxwell

November 15, 2021

Treatment of Factor Xa Inhibitor-Associated Bleeding with Andexanet Alfa: Full Results of ANNEXA-4

Presentation ISC 2019

Treatment of Factor Xa Inhibitor-Associated Bleeding with Andexanet Alfa: Full Results of ANNEXA-4

Presenter: Stuart J. Connolly

February 08, 2019

The Biggest News of 2018: TCTMD’s Top 10

News Daily News

The Biggest News of 2018: TCTMD’s Top 10

December 31, 2018

TCTMD’s Top 10 Most Popular Stories for June 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2018

July 02, 2018

TCTMD’s Top 10 Most Popular Stories for May 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2018

June 01, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

March 12, 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

March 05, 2018

News Conference News AHA 2015

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

November 05, 2015

News Industry News

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

September 16, 2015

News Daily News

初期研究显示利伐沙班拮抗剂安全、有效

December 30, 2013

News Daily News

Rivaroxaban Antidote Appears Safe, Effective in Early Study

December 30, 2013

News Daily News

El Antídoto de Rivaroxaban parece Seguro y Eficaz en un Estudio Preliminar

December 30, 2013

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.